Exogenous activation of the STING pathway enhances chemotherapy response, especially in PTEN-deficient tumors, by transforming the immunosuppressive tumor immune microenvironment (TIME) into an immunostimulatory state. This evidence concerns the gene STING1 and neoplasm.